School of Physiotherapy and Curtin Health Innovation Research Institute, Curtin University Royal Perth Hospital Lung Institute of Western Australia,
Respirology. 2011 Nov;16(8):1235-40. doi: 10.1111/j.1440-1843.2011.02030.x.
Individuals with pulmonary arterial hypertension (PAH) experience severely impaired quality of life. A disease-specific patient reported outcome measure for PAH (the Cambridge Pulmonary Hypertension Outcome Review--CAMPHOR) has recently been developed and validated in the UK, USA and Canada. It has demonstrated reliability and validity in PAH populations in these countries. The aim of this study was to assess the reliability and validity of the CAMPHOR in an Australian and New Zealand (NZ) PAH population.
Semistructured interviews were conducted with a cohort of 15 PAH patients (aged 68.9±10.0 years; 11 women) to determine the relevance of the CAMPHOR and ensure the terminology and language used was understandable and appropriate for our PAH population. The test-retest reliability, internal consistency and construct validity of the CAMPHOR were then examined in an Australian and NZ PAH population (n=61, aged 56.9±14.5 years; 48 women).
Data from the patient interviews confirmed that the CAMPHOR is appropriate for use in our PAH population. The three CAMPHOR scales (symptoms, activity limitations and quality of life) had excellent test-retest reliability (correlation coefficients (r(s))=0.86-0.94, P<0.01) and internal consistency (Cronbach's alpha coefficients=0.89-0.92). The CAMPHOR also demonstrated the ability to distinguish between individuals with PAH who differed according to World Health Organisation functional class.
We have shown the CAMPHOR to be valid and reliable in an Australian and NZ PAH population and recommend its use in clinical practice.
患有肺动脉高压（PAH）的个体经历严重受损的生活质量。一种专门针对 PAH 的患者报告结局测量工具（即剑桥肺高血压结局综述-CAMPHOR）最近已在英国、美国和加拿大得到开发和验证。它已在这些国家的 PAH 人群中证明了可靠性和有效性。本研究的目的是评估 CAMPHOR 在澳大利亚和新西兰（NZ）PAH 人群中的可靠性和有效性。
对 15 名 PAH 患者（年龄 68.9±10.0 岁；11 名女性）进行半结构化访谈，以确定 CAMPHOR 的相关性，并确保用于我们 PAH 人群的术语和语言是可理解且适当的。然后，在澳大利亚和 NZ PAH 人群（n=61，年龄 56.9±14.5 岁；48 名女性）中检查了 CAMPHOR 的测试-重测信度、内部一致性和结构有效性。
患者访谈的数据证实，CAMPHOR 适合用于我们的 PAH 人群。CAMPHOR 的三个量表（症状、活动受限和生活质量）具有极好的测试-重测信度（相关系数（r(s)）=0.86-0.94，P<0.01）和内部一致性（克朗巴赫's alpha 系数=0.89-0.92）。CAMPHOR 还表现出能够区分根据世界卫生组织功能分类而不同的 PAH 个体的能力。
我们已经证明 CAMPHOR 在澳大利亚和 NZ PAH 人群中是有效和可靠的，并建议在临床实践中使用它。
